Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16816921 | 1.00 | GRM4 (0.39) | GRM4GRM8CYP1A2MEN1CYP3A4 | |
| Water SCHEMBL6956683 | 0.99 | GRM8 (0.38) | GRM4GRM8CYP1A2MEN1CYP3A4 | |
| SCHEMBL457188 | 0.75 | TDP1 (0.40) | GRM4GRM8CYP1A2MEN1KMT2A | |
| SCHEMBL7678184 | 0.75 | TDP1 (0.40) | GRM4GRM8CYP1A2MEN1KMT2A | |
| SCHEMBL4924646 | 0.73 | BACE1 (0.41) | GRM4GRM8MEN1KMT2ABACE1 | |
| SCHEMBL4030499 | 0.71 | GRM8 (0.54) | GRM4GRM8CYP1A2MEN1CYP3A4 | |
| SCHEMBL872295 | 0.71 | BACE1 (0.39) | GRM4GRM8MEN1KMT2ABACE1 | |
| SCHEMBL385176 | 0.70 | GRIA2 (0.51) | CYP1A2MEN1CYP3A4KMT2ANPSR1 | |
| SCHEMBL385177 | 0.70 | GRIA2 (0.51) | CYP1A2MEN1CYP3A4KMT2ANPSR1 | |
| SCHEMBL9682909 | 0.69 | CRHBP (0.42) | CYP1A2MEN1KMT2ABACE1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | TREVENA, INC. | 2024-01-25 | — | — | US | claimed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | claimed |
| EP-4127157-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2022072560-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2021216529-A1 | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | TREVENA, INC. (US) | 2021-10-28 | — | — | WO | claimed |
| US-20210324005-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | TREVENA, INC. | 2021-10-21 | — | — | US | claimed |
| WO-2021194908-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2021-09-30 | — | — | WO | claimed |
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2018-01-18 | — | — | US | claimed |
| US-8993511-B2 | β-arrestin effectors and compositions and methods of use thereof | TREVENA, INC. (US) | 2015-03-31 | — | — | US | claimed |
| US-20140357562-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | TREVENA, INC. | 2014-12-04 | — | — | US | claimed |
| US-20140336123-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | TREVENA, INC. | 2014-11-13 | — | — | US | claimed |
| US-8809260-B2 | β-arrestin effectors and compositions and methods of use thereof | TREVENA, INC. (US) | 2014-08-19 | — | — | US | claimed |
| EP-2662079-A1 | Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells | Ordway Research Institute, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| US-20130274176-A1 | BETA-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | TREVENA, INC. (US) | 2013-10-17 | — | — | US | claimed |
| US-20120315320-A1 | USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS | NANOPHARMACEUTICALS LLC | 2012-12-13 | — | — | US | claimed |
| EP-2376101-A2 | ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | Trevena, Inc. (US) | 2011-10-19 | — | — | EP | claimed |
| US-20100184701-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | TREVENA, INC. | 2010-07-22 | — | — | US | claimed |
| WO-2010077339-A2 | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | TREVENA, INC. (US) | 2010-07-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | ARRB1, ADRB1, ADRB3 | GRM4 1186/4885GRM8 936/4885CYP1A2 4454/4885 |
| US-20140336123-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | ARRB1, ADRB1, ADRB3 | GRM4 1630/4885GRM8 1494/4885CYP1A2 4473/4885 |
| US-20210324005-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | ARRB1, ADRB1, FGB | GRM4 2119/4885GRM8 1765/4885CYP1A2 4688/4885 |
| US-20130274176-A1 | BETA-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | ARRB1, ADRB1, ADRB3 | GRM4 1630/4885GRM8 1494/4885CYP1A2 4473/4885 |
| US-20140357562-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | ARRB1, ADRB1, ADRB3 | GRM4 1630/4885GRM8 1494/4885CYP1A2 4473/4885 |
| US-20120315320-A1 | USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS | TSHR, TPO, THRA | GRM4 2709/4885GRM8 4335/4885CYP1A2 4049/4885 |
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | ARRB1, FGB, SARS1 | GRM4 2196/4885GRM8 1815/4885CYP1A2 4703/4885 |
| US-20100184701-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | ARRB1, ADRB1, ADRB3 | GRM4 1630/4885GRM8 1494/4885CYP1A2 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.